GE Healthcare today announced that the somo•v TM INSIGHT System was recognized as the category leader with the highest ranking in Women’s Imaging (Specialty) in the 2013 Best in KLAS Awards: Medical Equipment & Infrastructure Report. The Best in KLAS Awards Report ranked imaging, pharmacy automation and infrastructure vendors. This year, over 180 products were ranked by healthcare providers.
KLAS independently monitors vendor performance through the active participation of thousands of healthcare organizations. KLAS Performance Data represents the opinions of healthcare executives, managers, and clinicians from over 4,500 hospitals and 2,500 clinics, who have rated over 750 products and services from more than 200 vendors.
“Being recognized as the category leader in women’s imaging (Specialty) in the Best in KLAS award report further validates the impact of the somo•v ABUS in the breast cancer screening environment and the early detection of cancer in women with dense breasts. This is particularly gratifying as this recognition of leadership is the result of rankings from customers and users throughout the United States and Canada,” said Anders Wold, President and CEO of GE Ultrasound. “Our commitment to ABUS technology and making it available to more healthcare providers and patients around the world is a reflection of the company’s efforts in tackling breast cancer and our overall $1B investment to advance oncology solutions by 2016.”
Using proprietary technology to automate the ultrasound imaging process, the somo•v ABUS system was developed specifically for the breast cancer screening environment. Demonstrating a 35.7 percent improvement in cancer detection (sensitivity), the somo•v ABUS system is the only ultrasound device approved for breast cancer screening in the United States as an adjunct to mammography for asymptomatic women with dense breast tissue who have not had prior breast intervention.Rising breast cancer incidence and mortality represent a significant threat across the globe, according to a new global study commissioned by GE Healthcare and co-authored by Bengt Jönsson, Professor in Health Economics at the Stockholm School of Economics. Dense breast tissue not only increases the risk of breast cancer up to 4-6 times, but also makes cancer more difficult to detect using mammography, according to multiple large studies. One study, published in the New England Journal of Medicine, showed mammography sensitivity is reduced by 36 to 38 percent in women with dense breasts, as density masks the appearance of tumors (Boyd, et al, NEJM 2007:356:227-36M). As breast density goes up, the accuracy of mammograms goes down. Mammography is the most effective tool available for screening women for breast cancer; however, it does not work equally well for all women, particularly those with dense breasts, according to Marc Inciardi, MD, breast imaging radiologist at the University of Kansas Cancer Center in Kansas City and consultant to GE Healthcare. “We needed additional screening tools to improve breast cancer detection in women with dense breasts and ABUS has been proven to be beneficial and is easy to use. Enhancing our breast imaging capabilities without increasing the radiation dose, ABUS has quickly become a useful supplementary breast cancer detection tool in our practice.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts